What is Protagonist Therapeutics's stock issuance proceeds?

Protagonist Therapeutics (PTGX) reported stock issuance proceeds of $23.37M in Q1 2026.

How has Protagonist Therapeutics's stock issuance proceeds changed year-over-year?

Protagonist Therapeutics's stock issuance proceeds increased by 96.1% year-over-year, from $11.92M to $23.37M.

What does stock issuance proceeds mean?

Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.

Protagonist Therapeutics PTGX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

IncyteINCY

$97.93M+2,923%

Spyre Therapeutics, Inc.SYRE

$2.68M+1,128%

Regeneron PharmaceuticalsREGN

$163.1M+169%

Apogee Therapeutics, Inc.APGE

——

Kymera TherapeuticsKYMR

——

Immunovant, Inc.IMVT

——

Other financials

Income statement

See full

Revenue$56.4M+99.0%

Operating income-$3.6M+81.1%

Net income$3.8M+132%

EPS (diluted)$0.05+126%

Balance sheet

See full

Cash & equivalents$193.7M+38.7%

Total debt$9.8M-13.9%

Total equity$655.5M-4.9%

Total assets$697.5M-6.0%

Cash flow

See full

Operating cash flow-$48.9M-139%

CapEx$215.0K-60.6%

Free cash flow-$49.2M-139%

Valuation

See full

Market cap$7.26B+127%

Enterprise value$7.07B+130%

P/S98×+82.6×

Profitability

See full

Operating margin-192.4%-205pp

Net margin-154.9%-182pp

FCF margin-12,264.3%-12,527pp

Returns & leverage

See full

Return on equity-17.1%-26.1pp

Debt / equity0×0.0×

Current ratio17.8×+0.5×

Where this comes from

Reported directly by Protagonist Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.

The official record: Protagonist Therapeutics’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Protagonist Therapeutics's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Protagonist Therapeutics's stock issuance proceeds?: Protagonist Therapeutics (PTGX) reported stock issuance proceeds of $23.37M in Q1 2026.
How has Protagonist Therapeutics's stock issuance proceeds changed year-over-year?: Protagonist Therapeutics's stock issuance proceeds increased by 96.1% year-over-year, from $11.92M to $23.37M.
What does stock issuance proceeds mean?: Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.